Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed

Conditions: Glaucoma, Open-Angle
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01% ophthalmic solution

First Posted Date: 2011-12-12

Last Posted Date: 2014-03-28

Lead Sponsor: Allergan

Target Recruit Count: 387

Registration Number: NCT01489670

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: Travoprost 0.004% ophthalmic solution
Drug: Bimatoprost 0.01% ophthalmic solution

First Posted Date: 2011-11-03

Last Posted Date: 2013-09-13

Lead Sponsor: Alcon Research

Target Recruit Count: 84

Registration Number: NCT01464424

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Phase 4

Completed

Conditions: Hypotrichosis

Interventions: Drug: bimatoprost ophthalmic solution 0.03%
Drug: bimatoprost vehicle solution

First Posted Date: 2011-10-07

Last Posted Date: 2013-05-22

Lead Sponsor: Allergan

Target Recruit Count: 88

Registration Number: NCT01448525

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Phase 3

Terminated

Conditions: Glaucoma

Interventions: Drug: bimatoprost ophthalmic solution formulation A
Drug: timolol ophthalmic solution
Drug: bimatoprost vehicle

First Posted Date: 2011-08-31

Last Posted Date: 2015-10-02

Lead Sponsor: Allergan

Target Recruit Count: 6

Registration Number: NCT01426113

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Phase 3

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost vehicle solution
Drug: bimatoprost solution 0.03%

First Posted Date: 2011-07-12

Last Posted Date: 2019-07-08

Lead Sponsor: Allergan

Target Recruit Count: 173

Registration Number: NCT01391273

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Phase 3

Completed

Conditions: Eyelash Hypotrichosis

Interventions: Drug: bimatoprost solution 0.03%
Drug: bimatoprost vehicle solution

First Posted Date: 2011-07-12

Last Posted Date: 2019-07-08

Lead Sponsor: Allergan

Target Recruit Count: 36

Registration Number: NCT01391286

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Phase 4

Completed

Conditions: Hypotrichosis

Interventions: Drug: topical bimatoprost

First Posted Date: 2011-07-06

Last Posted Date: 2012-06-15

Lead Sponsor: Kenneth Beer

Target Recruit Count: 20

Registration Number: NCT01387906

Locations: 🇺🇸
Kenneth R. Beer, M.D. ,PA, West Palm Beach, Florida, United States

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Phase 2

Completed

Conditions: Baldness
Alopecia

Interventions: Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C
Drug: bimatoprost vehicle solution
Drug: minoxidil 2% solution
Drug: bimatoprost Formulation A

First Posted Date: 2011-03-29

Last Posted Date: 2014-04-09

Lead Sponsor: Allergan

Target Recruit Count: 306

Registration Number: NCT01325350

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Phase 2

Completed

Conditions: Alopecia
Baldness
Alopecia, Androgenetic

Interventions: Drug: bimatoprost Formulation A
Drug: bimatoprost vehicle solution
Drug: minoxidil 5% solution
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C

First Posted Date: 2011-03-29

Last Posted Date: 2014-04-10

Lead Sponsor: Allergan

Target Recruit Count: 307

Registration Number: NCT01325337

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 4

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: bimatoprost 0.01% ophthalmic solution
Drug: bimatoprost 0.03% ophthalmic solution

First Posted Date: 2011-02-18

Last Posted Date: 2018-09-17

Lead Sponsor: Allergan

Target Recruit Count: 806

Registration Number: NCT01298700

Locations: 🇮🇱
Glaucoma Service The Rabin Medical Center, Petach Tiqva, Israel
🇮🇱
Kaplan Medical Center, Rehovot, Israel
🇧🇪
UZ Leuven, Leuven, Belgium

and more 47 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy